Refreshed just now
FDA seeks proposals for advanced research and development of regulatory science under FY27 BAA FDABAA-27-00123, with responses due January 22, 2027.
Why it’s here: This FDA BAA for advanced regulatory science R&D relates to biotechnology policy and FDA regulation of novel therapies, though the notice has no description and the specific technology focus is unclear.
Trace across the boardItem
BAAFDA OFFICE OF ACQ GRANT SVCS5d agoFDA seeks proposals for advanced research and development of regulatory science under FY27 BAA FDABAA-27-00123, with responses due January 22, 2027.Closes in 61 daysFDABAA-27-00123BiotechLifecycle24 linked
Coverage
1 outlets · first seen 12d agoConnected
24 links- MoneyFY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceBoth involve Food and Drug Administration, Department of Health and Human Services, FDABAA-27-00123
- NewsInside the world of San Francisco 'peptide parties' — including one aboard a World War II shipBoth involve Food and Drug Administration, Department of Health and Human Services
- NewsTrump administration releases roadmap to boost clinical AIBoth involve Food and Drug Administration, Department of Health and Human Services
- HillStrategic Planning: FDA Could Further Strengthen Robust IT Modernization PlanBoth involve Food and Drug Administration, Department of Health and Human Services
- HillEarly-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; AvailabilityBoth involve Food and Drug Administration, Department of Health and Human Services
- NewsCancer Vaccines Are Advancing. Can Regulators Keep Up?Both involve Food and Drug Administration, Department of Health and Human Services
- NewsBill Cassidy says Trump’s FDA pick faces uncertain committee voteBoth involve Food and Drug Administration, Department of Health and Human Services
- MoneyTranslational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)Both involve Food and Drug Administration, Department of Health and Human Services
- NewsSTAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time comingBoth involve Food and Drug Administration
- NewsFDA warns against online weight-loss drugs containing uncertain ingredientsBoth involve Food and Drug Administration
- NewsUS FDA orders new eye risk warnings for Ozempic, ZepboundBoth involve Food and Drug Administration
- NewsSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionBoth involve Food and Drug Administration
- HillComments due: Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft GuidanceBoth involve Food and Drug Administration
- HillComments due: Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation CapabilitiesBoth involve Food and Drug Administration
- HillComments due: Potency Assessment of Active Immunotherapy Products; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for FeedbackBoth involve Food and Drug Administration
- HillComments due: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for IndustryBoth involve Food and Drug Administration
- HillComments due: FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in BiologicsBoth involve Food and Drug Administration
- HillComments due: BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy DocumentBoth involve Food and Drug Administration
- HillCRS Report: Novel Gene Therapies for Blood DisordersBoth involve Food and Drug Administration
- HillComments due: Early-Phase IND Protocol Recommendations for Solid Tumors; Guidance for Industry - Draft GuidanceBoth involve Food and Drug Administration
- HillMoolenaar to FDA: "Chinese Clinical Data Poses Real Risks for Patients"Both involve Food and Drug Administration
- NewsSTAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsBoth involve Food and Drug Administration
- HillComments due: PSG_218436 - Draft Guidance on RemibrutinibBoth involve Food and Drug Administration
About
- Food and Drug Administration
- Department of Health and Human Services